Hypnosis in Treating Hot Flashes in Breast Cancer Survivors
Breast Cancer, Cancer Survivor, Hot Flashes
About this trial
This is an interventional supportive care trial for Breast Cancer focused on measuring cancer survivor, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer, breast cancer in situ, inflammatory breast cancer, hot flashes
Eligibility Criteria
DISEASE CHARACTERISTICS: History of primary breast cancer No evidence of detectable disease At least 14 hot flashes per week for ≥ 1 month by self-reporting Hormone receptor status not specified PATIENT CHARACTERISTICS: Female Life expectancy > 6 months Menopausal status not specified Outpatient status No medical or psychiatric condition that would preclude study participation PRIOR CONCURRENT THERAPY: Concurrent antihormonal agents for breast cancer (e.g., tamoxifen or raloxifene) allowed provided the patient has been on them for ≥ 1 month No other concurrent hormonal therapy No other putative therapies for hot flashes ≥ 1 month prior to study entry Concurrent vitamin E allowed No other concurrent treatment for hot flashes No concurrent cytotoxic chemotherapy Not concurrently using hypnosis for any reason
Sites / Locations
- Scott and White Cancer InstituteRecruiting